vs
百通（BDC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
百通的季度营收约是Royalty Pharma plc的1.2倍（$720.1M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 9.4%，领先25.0%），百通同比增速更快（8.1% vs 4.8%），过去两年百通的营收复合增速更高（9.2% vs 4.6%）
百通公司是美国上市跨国企业，专注于端到端网络、安全及连接产品的设计、生产与销售，业务覆盖工业自动化解决方案、智能建筑、宽带及5G三大核心领域，为各行业客户提供可靠的通信连接相关产品与服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
BDC vs RPRX — 直观对比
营收规模更大
BDC
是对方的1.2倍
$622.0M
营收增速更快
BDC
高出3.3%
4.8%
净利率更高
RPRX
高出25.0%
9.4%
两年增速更快
BDC
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $720.1M | $622.0M |
| 净利润 | $67.9M | $214.2M |
| 毛利率 | 36.6% | — |
| 营业利润率 | 12.2% | 62.4% |
| 净利率 | 9.4% | 34.4% |
| 营收同比 | 8.1% | 4.8% |
| 净利润同比 | 16.3% | 2.9% |
| 每股收益（稀释后） | $1.70 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDCRPRX
| Q1 26 | $720.1M | — | ||
| Q4 25 | $720.1M | $622.0M | ||
| Q3 25 | $698.2M | $609.3M | ||
| Q2 25 | $672.0M | $578.7M | ||
| Q1 25 | $624.9M | $568.2M | ||
| Q4 24 | $666.0M | $593.6M | ||
| Q3 24 | $654.9M | $564.7M | ||
| Q2 24 | $604.3M | $537.3M |
净利润BDCRPRX
| Q1 26 | $67.9M | — | ||
| Q4 25 | $67.9M | $214.2M | ||
| Q3 25 | $56.7M | $288.2M | ||
| Q2 25 | $61.0M | $30.2M | ||
| Q1 25 | $51.9M | $238.3M | ||
| Q4 24 | $58.4M | $208.2M | ||
| Q3 24 | $53.7M | $544.0M | ||
| Q2 24 | $49.0M | $102.0M |
毛利率BDCRPRX
| Q1 26 | 36.6% | — | ||
| Q4 25 | 36.6% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 39.3% | — | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.5% | — |
营业利润率BDCRPRX
| Q1 26 | 12.2% | — | ||
| Q4 25 | 12.2% | 62.4% | ||
| Q3 25 | 10.9% | 70.1% | ||
| Q2 25 | 11.8% | 36.3% | ||
| Q1 25 | 11.6% | 94.0% | ||
| Q4 24 | 10.4% | 60.9% | ||
| Q3 24 | 11.5% | — | ||
| Q2 24 | 11.4% | 50.2% |
净利率BDCRPRX
| Q1 26 | 9.4% | — | ||
| Q4 25 | 9.4% | 34.4% | ||
| Q3 25 | 8.1% | 47.3% | ||
| Q2 25 | 9.1% | 5.2% | ||
| Q1 25 | 8.3% | 41.9% | ||
| Q4 24 | 8.8% | 35.1% | ||
| Q3 24 | 8.2% | 96.3% | ||
| Q2 24 | 8.1% | 19.0% |
每股收益（稀释后）BDCRPRX
| Q1 26 | $1.70 | — | ||
| Q4 25 | $1.70 | $0.49 | ||
| Q3 25 | $1.41 | $0.67 | ||
| Q2 25 | $1.53 | $0.07 | ||
| Q1 25 | $1.27 | $0.55 | ||
| Q4 24 | $1.41 | $0.46 | ||
| Q3 24 | $1.30 | $1.21 | ||
| Q2 24 | $1.19 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $389.9M | $618.7M |
| 总债务越低越好 | $1.3B | $9.0B |
| 股东权益账面价值 | $1.3B | $9.7B |
| 总资产 | — | $19.6B |
| 负债/权益比越低杠杆越低 | 1.02× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资BDCRPRX
| Q1 26 | $389.9M | — | ||
| Q4 25 | $389.9M | $618.7M | ||
| Q3 25 | $314.3M | $938.9M | ||
| Q2 25 | $301.5M | $631.9M | ||
| Q1 25 | $259.0M | $1.1B | ||
| Q4 24 | $370.3M | $929.0M | ||
| Q3 24 | $323.0M | $950.1M | ||
| Q2 24 | $564.8M | $1.8B |
总债务BDCRPRX
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益BDCRPRX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.2B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
总资产BDCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $19.6B | ||
| Q3 25 | $3.4B | $19.3B | ||
| Q2 25 | $3.4B | $18.3B | ||
| Q1 25 | $3.3B | $17.6B | ||
| Q4 24 | $3.3B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.5B | $17.7B |
负债/权益比BDCRPRX
| Q1 26 | 1.02× | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $354.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $121.3M | — |
| 自由现金流率自由现金流/营收 | 16.8% | — |
| 资本支出强度资本支出/营收 | 18.9% | — |
| 现金转化率经营现金流/净利润 | 5.23× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $364.7M | — |
8季度趋势，按日历期对齐
经营现金流BDCRPRX
| Q1 26 | $354.9M | — | ||
| Q4 25 | $160.4M | $827.1M | ||
| Q3 25 | $105.0M | $702.6M | ||
| Q2 25 | $82.0M | $364.0M | ||
| Q1 25 | $7.4M | $596.1M | ||
| Q4 24 | $174.7M | $742.5M | ||
| Q3 24 | $91.7M | $703.6M | ||
| Q2 24 | $83.0M | $658.2M |
自由现金流BDCRPRX
| Q1 26 | $121.3M | — | ||
| Q4 25 | $121.3M | — | ||
| Q3 25 | $65.3M | — | ||
| Q2 25 | $56.9M | — | ||
| Q1 25 | $-24.8M | — | ||
| Q4 24 | $116.4M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $61.0M | — |
自由现金流率BDCRPRX
| Q1 26 | 16.8% | — | ||
| Q4 25 | 16.8% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 8.5% | — | ||
| Q1 25 | -4.0% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 10.1% | — |
资本支出强度BDCRPRX
| Q1 26 | 18.9% | — | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 3.6% | — |
现金转化率BDCRPRX
| Q1 26 | 5.23× | — | ||
| Q4 25 | 2.36× | 3.86× | ||
| Q3 25 | 1.85× | 2.44× | ||
| Q2 25 | 1.34× | 12.06× | ||
| Q1 25 | 0.14× | 2.50× | ||
| Q4 24 | 2.99× | 3.57× | ||
| Q3 24 | 1.71× | 1.29× | ||
| Q2 24 | 1.69× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
